Veradermics (MANE) director receives grant of 43,000 stock options

Rhea-AI Filing Summary

Veradermics, Inc. director Katarina Pance received a grant of stock options for 43,000 shares of common stock on February 3, 2026. The options carry an exercise price of $17 per share and are held as a direct ownership position.

The award was reported as an acquisition under a grant or award transaction code. According to the terms, the option will become fully vested and exercisable on February 3, 2027, which is the first anniversary of the vesting commencement date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pance Katarina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	43,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 43,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/05/2026 - 07:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pance Katarina

(Last) (First) (Middle)

929 MAIN STREET

SUITE 200

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/03/2026		A		43,000		(1)	02/03/2036	Common Stock	43,000	$0	43,000	D

Explanation of Responses:

1. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.

	/s/ Sasha Keough, attorney-in-fact for Katarina Pance	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veradermics (MANE) director Katarina Pance report on this Form 4?

Director Katarina Pance reported receiving a grant of stock options for 43,000 shares of Veradermics common stock. The transaction is classified as an acquisition via grant or award, reflecting equity-based compensation rather than an open-market stock purchase or sale.

What are the key terms of the Veradermics (MANE) stock options granted to Katarina Pance?

The stock options give the right to buy 43,000 shares of Veradermics common stock at an exercise price of $17 per share. All 43,000 options are held directly and relate to a single grant transaction dated February 3, 2026, as reported on the Form 4.

When do Katarina Pance’s Veradermics (MANE) stock options vest and become exercisable?

The options will be fully vested and exercisable on February 3, 2027. This vesting date is defined as the first anniversary of the vesting commencement date, meaning Pance must wait one year from February 3, 2026 before exercising any of the granted options.

How many Veradermics (MANE) derivative securities does Katarina Pance own after this transaction?

After the reported grant, Katarina Pance beneficially owns 43,000 derivative securities in the form of stock options. These options each relate to one share of Veradermics common stock and are shown as directly owned following the February 3, 2026 grant transaction.

Is the Form 4 transaction for Veradermics (MANE) a purchase or a compensation grant?

The Form 4 describes a compensation-related grant, not an open-market purchase. The transaction code is reported as a grant, award, or other acquisition, indicating the 43,000 stock options were awarded to director Katarina Pance as part of an equity compensation arrangement.